Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial
Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Attia, Amr Atef [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2023 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The cardiothoracic surgeon - [Berlin, Heidelberg] : Springer, 2019, 31(2023), 1 vom: 17. Juli |
|---|---|
| Übergeordnetes Werk: |
volume:31 ; year:2023 ; number:1 ; day:17 ; month:07 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43057-023-00103-z |
|---|
| Katalog-ID: |
SPR052271404 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052271404 | ||
| 003 | DE-627 | ||
| 005 | 20230717064618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230717s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43057-023-00103-z |2 doi | |
| 035 | |a (DE-627)SPR052271404 | ||
| 035 | |a (SPR)s43057-023-00103-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Attia, Amr Atef |e verfasserin |0 (orcid)0000-0002-1941-5869 |4 aut | |
| 245 | 1 | 0 | |a Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. | ||
| 650 | 4 | |a Heart Valves Surgery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardioplegia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Propofol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardioprotective Effect |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Torky, Mohammad Abd Elmoneim |4 aut | |
| 700 | 1 | |a Abo Elnasr, Mohamed Mahmoud |4 aut | |
| 700 | 1 | |a Wahby, Ehab Abd Elmonem |4 aut | |
| 700 | 1 | |a Taha, Abd Elhady Mohammed |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The cardiothoracic surgeon |d [Berlin, Heidelberg] : Springer, 2019 |g 31(2023), 1 vom: 17. Juli |w (DE-627)1688112510 |w (DE-600)3006146-5 |x 2662-2203 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:1 |g day:17 |g month:07 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43057-023-00103-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 1 |b 17 |c 07 | ||
| author_variant |
a a a aa aaa m a e t mae maet e m m a emm emma e a e w eae eaew a e m t aem aemt |
|---|---|
| matchkey_str |
article:26622203:2023----::adortciefetfrpflnadolgaoprdoytmcrpflnervles |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1186/s43057-023-00103-z doi (DE-627)SPR052271404 (SPR)s43057-023-00103-z-e DE-627 ger DE-627 rakwb eng Attia, Amr Atef verfasserin (orcid)0000-0002-1941-5869 aut Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 Torky, Mohammad Abd Elmoneim aut Abo Elnasr, Mohamed Mahmoud aut Wahby, Ehab Abd Elmonem aut Taha, Abd Elhady Mohammed aut Enthalten in The cardiothoracic surgeon [Berlin, Heidelberg] : Springer, 2019 31(2023), 1 vom: 17. Juli (DE-627)1688112510 (DE-600)3006146-5 2662-2203 nnns volume:31 year:2023 number:1 day:17 month:07 https://dx.doi.org/10.1186/s43057-023-00103-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 31 2023 1 17 07 |
| spelling |
10.1186/s43057-023-00103-z doi (DE-627)SPR052271404 (SPR)s43057-023-00103-z-e DE-627 ger DE-627 rakwb eng Attia, Amr Atef verfasserin (orcid)0000-0002-1941-5869 aut Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 Torky, Mohammad Abd Elmoneim aut Abo Elnasr, Mohamed Mahmoud aut Wahby, Ehab Abd Elmonem aut Taha, Abd Elhady Mohammed aut Enthalten in The cardiothoracic surgeon [Berlin, Heidelberg] : Springer, 2019 31(2023), 1 vom: 17. Juli (DE-627)1688112510 (DE-600)3006146-5 2662-2203 nnns volume:31 year:2023 number:1 day:17 month:07 https://dx.doi.org/10.1186/s43057-023-00103-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 31 2023 1 17 07 |
| allfields_unstemmed |
10.1186/s43057-023-00103-z doi (DE-627)SPR052271404 (SPR)s43057-023-00103-z-e DE-627 ger DE-627 rakwb eng Attia, Amr Atef verfasserin (orcid)0000-0002-1941-5869 aut Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 Torky, Mohammad Abd Elmoneim aut Abo Elnasr, Mohamed Mahmoud aut Wahby, Ehab Abd Elmonem aut Taha, Abd Elhady Mohammed aut Enthalten in The cardiothoracic surgeon [Berlin, Heidelberg] : Springer, 2019 31(2023), 1 vom: 17. Juli (DE-627)1688112510 (DE-600)3006146-5 2662-2203 nnns volume:31 year:2023 number:1 day:17 month:07 https://dx.doi.org/10.1186/s43057-023-00103-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 31 2023 1 17 07 |
| allfieldsGer |
10.1186/s43057-023-00103-z doi (DE-627)SPR052271404 (SPR)s43057-023-00103-z-e DE-627 ger DE-627 rakwb eng Attia, Amr Atef verfasserin (orcid)0000-0002-1941-5869 aut Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 Torky, Mohammad Abd Elmoneim aut Abo Elnasr, Mohamed Mahmoud aut Wahby, Ehab Abd Elmonem aut Taha, Abd Elhady Mohammed aut Enthalten in The cardiothoracic surgeon [Berlin, Heidelberg] : Springer, 2019 31(2023), 1 vom: 17. Juli (DE-627)1688112510 (DE-600)3006146-5 2662-2203 nnns volume:31 year:2023 number:1 day:17 month:07 https://dx.doi.org/10.1186/s43057-023-00103-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 31 2023 1 17 07 |
| allfieldsSound |
10.1186/s43057-023-00103-z doi (DE-627)SPR052271404 (SPR)s43057-023-00103-z-e DE-627 ger DE-627 rakwb eng Attia, Amr Atef verfasserin (orcid)0000-0002-1941-5869 aut Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 Torky, Mohammad Abd Elmoneim aut Abo Elnasr, Mohamed Mahmoud aut Wahby, Ehab Abd Elmonem aut Taha, Abd Elhady Mohammed aut Enthalten in The cardiothoracic surgeon [Berlin, Heidelberg] : Springer, 2019 31(2023), 1 vom: 17. Juli (DE-627)1688112510 (DE-600)3006146-5 2662-2203 nnns volume:31 year:2023 number:1 day:17 month:07 https://dx.doi.org/10.1186/s43057-023-00103-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 31 2023 1 17 07 |
| language |
English |
| source |
Enthalten in The cardiothoracic surgeon 31(2023), 1 vom: 17. Juli volume:31 year:2023 number:1 day:17 month:07 |
| sourceStr |
Enthalten in The cardiothoracic surgeon 31(2023), 1 vom: 17. Juli volume:31 year:2023 number:1 day:17 month:07 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Heart Valves Surgery Cardioplegia Propofol Cardioprotective Effect |
| isfreeaccess_bool |
true |
| container_title |
The cardiothoracic surgeon |
| authorswithroles_txt_mv |
Attia, Amr Atef @@aut@@ Torky, Mohammad Abd Elmoneim @@aut@@ Abo Elnasr, Mohamed Mahmoud @@aut@@ Wahby, Ehab Abd Elmonem @@aut@@ Taha, Abd Elhady Mohammed @@aut@@ |
| publishDateDaySort_date |
2023-07-17T00:00:00Z |
| hierarchy_top_id |
1688112510 |
| id |
SPR052271404 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR052271404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230717064618.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230717s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43057-023-00103-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR052271404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43057-023-00103-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Attia, Amr Atef</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1941-5869</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Heart Valves Surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardioplegia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Propofol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardioprotective Effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Torky, Mohammad Abd Elmoneim</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abo Elnasr, Mohamed Mahmoud</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahby, Ehab Abd Elmonem</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taha, Abd Elhady Mohammed</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The cardiothoracic surgeon</subfield><subfield code="d">[Berlin, Heidelberg] : Springer, 2019</subfield><subfield code="g">31(2023), 1 vom: 17. Juli</subfield><subfield code="w">(DE-627)1688112510</subfield><subfield code="w">(DE-600)3006146-5</subfield><subfield code="x">2662-2203</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:17</subfield><subfield code="g">month:07</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43057-023-00103-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">17</subfield><subfield code="c">07</subfield></datafield></record></collection>
|
| author |
Attia, Amr Atef |
| spellingShingle |
Attia, Amr Atef misc Heart Valves Surgery misc Cardioplegia misc Propofol misc Cardioprotective Effect Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| authorStr |
Attia, Amr Atef |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1688112510 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2662-2203 |
| topic_title |
Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial Heart Valves Surgery (dpeaa)DE-He213 Cardioplegia (dpeaa)DE-He213 Propofol (dpeaa)DE-He213 Cardioprotective Effect (dpeaa)DE-He213 |
| topic |
misc Heart Valves Surgery misc Cardioplegia misc Propofol misc Cardioprotective Effect |
| topic_unstemmed |
misc Heart Valves Surgery misc Cardioplegia misc Propofol misc Cardioprotective Effect |
| topic_browse |
misc Heart Valves Surgery misc Cardioplegia misc Propofol misc Cardioprotective Effect |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
The cardiothoracic surgeon |
| hierarchy_parent_id |
1688112510 |
| hierarchy_top_title |
The cardiothoracic surgeon |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1688112510 (DE-600)3006146-5 |
| title |
Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| ctrlnum |
(DE-627)SPR052271404 (SPR)s43057-023-00103-z-e |
| title_full |
Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| author_sort |
Attia, Amr Atef |
| journal |
The cardiothoracic surgeon |
| journalStr |
The cardiothoracic surgeon |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| author_browse |
Attia, Amr Atef Torky, Mohammad Abd Elmoneim Abo Elnasr, Mohamed Mahmoud Wahby, Ehab Abd Elmonem Taha, Abd Elhady Mohammed |
| container_volume |
31 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Attia, Amr Atef |
| doi_str_mv |
10.1186/s43057-023-00103-z |
| normlink |
(ORCID)0000-0002-1941-5869 |
| normlink_prefix_str_mv |
(orcid)0000-0002-1941-5869 |
| title_sort |
cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| title_auth |
Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| abstract |
Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. © The Author(s) 2023 |
| abstractGer |
Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. © The Author(s) 2023 |
| abstract_unstemmed |
Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726. © The Author(s) 2023 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial |
| url |
https://dx.doi.org/10.1186/s43057-023-00103-z |
| remote_bool |
true |
| author2 |
Torky, Mohammad Abd Elmoneim Abo Elnasr, Mohamed Mahmoud Wahby, Ehab Abd Elmonem Taha, Abd Elhady Mohammed |
| author2Str |
Torky, Mohammad Abd Elmoneim Abo Elnasr, Mohamed Mahmoud Wahby, Ehab Abd Elmonem Taha, Abd Elhady Mohammed |
| ppnlink |
1688112510 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43057-023-00103-z |
| up_date |
2024-07-04T02:06:32.934Z |
| _version_ |
1803612368861659136 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR052271404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230717064618.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230717s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43057-023-00103-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR052271404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43057-023-00103-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Attia, Amr Atef</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1941-5869</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardioprotective effect of propofol in cardioplegia compared to systemic propofol in heart valves surgery; a randomized controlled trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Myocardial protection is still a focus of ongoing research. Propofol is used widely during the induction of anaesthesia in cardiac surgery. So, this triggers us to investigate the cardioprotective effect of the propofol when added to the cardioplegia compared to systemic propofol by measuring the troponin T level. Methods This clinical randomized controlled trial was carried out on 150 patients operated for elective valvular heart surgery. Patients were assigned into three equal groups: Group 1: received propofol in the cardioplegia, Group 2: received propofol injection in the aortic line before and after the aortic cross-clamp, and Group 3 (control group): patients without propofol in the cardioplegia or aortic line. All patients were subjected to full medical histories, physical examinations, routine tests, and echocardiography. Cardiac troponin T was measured before surgery and 4 times postoperatively. Results In group 1, there was a significant improvement in troponin T level at the last reading compared with the control group (mean ± SD. of group 1 was 246.4 ± 131.4, mean ± SD. of group 3 was 317.0 ± 117.9, p = 0.031), denoting propofol's cardioprotective effect when added as a cardioplegia additive. In group 2, there was a significant improvement of troponin T level at the last reading compared with the group 1 and control group (mean ± SD. of group 2 was 202.54 ± 156.03, mean ± SD. of group 3 was 317.0 ± 117.9, p < 0.001), denoting propofol's more cardioprotective effect when used systemically during cardiopulmonary bypass than when added as a cardioplegia additive. Conclusions In valvular cardiac surgery, propofol has an additional cardioprotective effect and a superior cardiac outcome when administered systematically during cardiopulmonary bypass rather than added to cardioplegia. Trial registration Pan African Clinical Trials Register PACTR201907764652028. Registered on 01 July 2019, retrospectively registered, https://pactr.samrc.ac.za/ TrialDisplay.aspx?TrialID = 5726.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Heart Valves Surgery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardioplegia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Propofol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardioprotective Effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Torky, Mohammad Abd Elmoneim</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abo Elnasr, Mohamed Mahmoud</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wahby, Ehab Abd Elmonem</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taha, Abd Elhady Mohammed</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The cardiothoracic surgeon</subfield><subfield code="d">[Berlin, Heidelberg] : Springer, 2019</subfield><subfield code="g">31(2023), 1 vom: 17. Juli</subfield><subfield code="w">(DE-627)1688112510</subfield><subfield code="w">(DE-600)3006146-5</subfield><subfield code="x">2662-2203</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:17</subfield><subfield code="g">month:07</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43057-023-00103-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">17</subfield><subfield code="c">07</subfield></datafield></record></collection>
|
| score |
7.3998566 |